Alliance Pharma plc

Equities

APH

GB0031030819

Pharmaceuticals

Delayed London S.E. 04:00:34 2024-06-18 am EDT 5-day change 1st Jan Change
32.79 GBX -0.17% Intraday chart for Alliance Pharma plc -4.67% -19.03%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Amberen, Brand of Alliance Pharma plc, Announces Launch of Amberen ENERGY MOOD SLEEP Gummies CI
Alliance Pharma plc Announces the Appointment of Nicholas John Sedgwick as Director CI
Alliance Pharma drops as CEO departs, delays results again AN
European Equities Close Higher in Wednesday Trading; Siemens Energy, Alliance Pharma CEOs to Step Down MT
Alliance Pharma Chief Executive to Leave; New CEO to Start May 13 MT
AIM WINNERS & LOSERS: Mobile Tornado wins deal; boohoo loss widens AN
Alliance Pharma plc Announces CEO Changes CI
Jefferies cuts AJ Bell; Deutsche likes ConvaTec AN
EARNINGS: Lok'n Store has "positive but muted" growth as Shurgard bids AN
Alliance Pharma plc Announces Delay in Publication of Preliminary Earnings Results for the Year Ended December 31, 2023 CI
Alliance Pharma appoints chair; FireAngel sales down AN
Alliance Pharma Chair to Step Down; Successor Named MT
Alliance Pharma plc Announces Board Changes CI
Jefferies raises Spirax-Sarco; cuts Victrex AN
Alliance Pharma reports annual boost in revenue; eyes flat 2024 profit AN
Alliance Pharma plc Announces Appointment of Non-Executive Directors CI
Barclays ups Rio Tinto; Liberum likes Indivior AN
Barclays cuts United Utilities and Severn Trent AN
Alliance Pharma first half profit plunges, stops dividend payout AN
Earnings Flash (APH.L) ALLIANCE PHARMA Posts H1 Revenue GBP81.4M MT
Earnings Flash (APH.L) ALLIANCE PHARMA Posts H1 EPS GBX0.94 MT
Alliance Pharma plc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023 CI
High demand, low supplies for Novo's weight-loss drug launch in Germany RE
Exane raises Segro; Goldman likes Aston Martin AN
Chart Alliance Pharma plc
More charts
Alliance Pharma plc is a United Kingdom-based consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.3285 GBP
Average target price
0.6529 GBP
Spread / Average Target
+98.74%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. APH Stock
  4. News Alliance Pharma plc
  5. European Equities Close Higher in Wednesday Trading; Siemens Energy, Alliance Pharma CEOs to Step Down